CD33 and hepatocellular carcinoma: Pooled data of 5 studies in which MDSCs were identified as “HLA-DRlow/−CD11b+CD33+” revealed that there was a significantly higher frequency of MDSCs in HCC patients compared to healthy controls (SMD = 3.68, 95% CI = 1.42–5.95, P = 0.001).